At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
Venetoclax and pegcrisantaspasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia
In Brief
A Phase 1 clinical trial evaluating Venetoclax and pegcrisantaspase for Relapsed or Refractory Acute Myeloid Leukemia. Completed, enrolled 27 participants across 1 site.
Detailed Summary
Evaluate the safety and tolerability of pegcrisantaspase in combination with venetoclax (Ven-PegC) and estimate the maximum tolerated doses and/or biologically active doses of Ven-PegC in patients with relapsed or refractory acute myeloid leukemia (R/R AML)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionSep 2024
Study CompletionMay 2025
TodayJul 2026
First PostedDec 14, 2020
Enrollment StartMar 10, 2021
Primary CompletionSep 1, 2024
Study CompletionMay 23, 2025
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.5 years ago
Interventions
Venetoclax and pegcrisantaspasedrug
Therapeutic